comprehensive -WSS

comprehensive

author：Wikipedia 2025-10-02 20:47:01 - browse：75657

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The blockbuster weight loss and diabetes drug sold by Eli Lilly also appears to improve fatty liver disease, according to early clinical trial data the pharmaceutical company released Tuesday.

Eli Lilly reported during its fourth-quarter earnings call that tirzepatide, which is sold commercially as Mounjaro or Zepbound, succeeded in a Phase 2 test as a treatment for the liver disease MASH. Around 74% of adults in the trial taking the drug were free of MASH after 52 weeks, compared to approximately 13% of the placebo group.

MASH, formerly known as NASH, is a liver disease characterized by excess fat and inflammation. The chronic inflammation can also lead to liver scarring, or fibrosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Sage hopes for a blockbuster in antidepressant now before FDA

leisure time

WSS

Sage hopes for a blockbuster in antidepressant now before FDA

In key trial, Verve's treatment lowers cholesterol levels in patients

FDA's Woodcock to retire early next year

Sage hopes for a blockbuster in antidepressant now before FDA

Morphosys mixed study results for blood cancer drug

A daunting task: navigating dual Medicare, Medicaid eligibility

knowledge

comprehensive

focus

Medicare proposal to cover medical devices draws a mixed reaction

Childhood cancer progress stalls for Black, Hispanic kids: Report

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

23andMe had bad news about my health. I wish a person had delivered it

Infectious disease expert Jeanne Marrazzo assumes Fauci role

Heart attack and stroke risk calculators need revising

Physician groups backed by private equity giant lobby on mergers

Apple is now the first public company to be valued at $3 trillion

Micronoma's microbiome cancer diagnostic approach under fire

hotspot

In key trial, Verve's treatment lowers cholesterol levels in patients

What the US credit downgrade means for the economy, your finances

What the airline industry can learn from medicine

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

Anthos stroke drug appears safer than common blood thinner

What the airline industry can learn from medicine

focus

explore

leisure time

focus